|Day Low/High||22.79 / 23.34|
|52 Wk Low/High||17.20 / 28.45|
Here are updates on small biotech/biopharma names I have profiled before.
Let's look at a couple of companies we have covered on these pages before.
One big change over the last few years has been the struggle of small concerns to penetrate mass markets even with approved and superior drugs.
One already is up nicely on its results, while the other two should issue reports of interest in the next few days.
Traders look like they have taken a neutral to bearish stance ahead of earnings.
A shortened week still brings key economic numbers and earnings results.
It's probably no surprise that my picks for 2019 come from the biotech/biopharma space.
We look at a slightly riskier part of the sector...that should be able to reach profitability with little to no additional funding needs.
Biotech ETFs could mitigate risk amid the sector's volatility, and names such as Exelixis, ANI Pharmaceuticals and Progenics hold promise.
Shares of the former Valeant Pharmaceuticals have rallied the past 12 months, but can the strength continue?
Ackman's fund bought the hotelier's stock in 2016 and cashed out the following year for a gain of about 30%.
It's weeks like this that I'm glad I have some 'dry powder' to deploy.
Former Kase Capital managing partner says Tesla shares likely to spiral downward.
For the first time in a decade, corporate share buybacks are taking up the largest portion of capital expenditures: Memo to Self: Companies are notorious poor market timers in buying their own shares. I give you such examples as Bausch Health Cos. ...
Both biotech stocks are at or near 52-week lows, but don't deserve to be.
Progenics and Tesaro are among sagging small-cap biotech stocks that could rebound in coming months.